366 related articles for article (PubMed ID: 21787173)
1. Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid.
Panes O; Padilla O; Matus V; Sáez CG; Berkovits A; Pereira J; Mezzano D
Platelets; 2012; 23(1):36-44. PubMed ID: 21787173
[TBL] [Abstract][Full Text] [Related]
2. Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis.
Yamamoto J; Yamashita T; Ikarugi H; Taka T; Hashimoto M; Ishii H; Watanabe S; Kovacs IB
Blood Coagul Fibrinolysis; 2003 Jan; 14(1):31-9. PubMed ID: 12544726
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.
Dai L; Bevan D; Rangarajan S; Sørensen B; Mitchell M
Haemophilia; 2011 Sep; 17(5):e944-8. PubMed ID: 21371192
[TBL] [Abstract][Full Text] [Related]
4. The potential role of platelet PAl-1 in t-PA mediated clot lysis of platelet rich plasma.
Serizawa K; Urano T; Kozima Y; Takada Y; Takada A
Thromb Res; 1993 Aug; 71(4):289-300. PubMed ID: 8236158
[TBL] [Abstract][Full Text] [Related]
5. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
6. A history of early stent thrombosis is associated with prolonged clot lysis time.
Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
[TBL] [Abstract][Full Text] [Related]
7. Peroxynitrite may affect fibrinolysis via the reduction of platelet-related fibrinolysis resistance and alteration of clot structure.
Misztal T; Rusak T; Brańska-Januszewska J; Ostrowska H; Tomasiak M
Free Radic Biol Med; 2015 Dec; 89():533-47. PubMed ID: 26454084
[TBL] [Abstract][Full Text] [Related]
8. The effect of long-term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patients.
Sabovic M; Zupan IP; Salobir B; Zupan I; Cernelc P; Lavre J; Vujkovac B
Thromb Haemost; 2005 Dec; 94(6):1245-50. PubMed ID: 16411401
[TBL] [Abstract][Full Text] [Related]
9. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
11. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
12. Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury.
Zentai C; van der Meijden PE; Braunschweig T; Hueck N; Honickel M; Spronk HM; Rossaint R; Grottke O
Anesth Analg; 2016 Jul; 123(1):38-48. PubMed ID: 27192476
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1995 May; 73(5):845-9. PubMed ID: 7482414
[TBL] [Abstract][Full Text] [Related]
14. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood.
Dirkmann D; Görlinger K; Gisbertz C; Dusse F; Peters J
Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068
[TBL] [Abstract][Full Text] [Related]
15. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
16. Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure.
Mezzano D; Panes O; Muñoz B; Pais E; Tagle R; González F; Mezzano S; Barriga F; Pereira J
Thromb Haemost; 1999 Oct; 82(4):1250-4. PubMed ID: 10544908
[TBL] [Abstract][Full Text] [Related]
17. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
He S; Johnsson H; Zabczyk M; Hultenby K; Cao H; Blombäck M
Br J Haematol; 2013 Mar; 160(6):806-16. PubMed ID: 23360261
[TBL] [Abstract][Full Text] [Related]
18. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
Drabik L; Wołkow P; Undas A
Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
[TBL] [Abstract][Full Text] [Related]
19. The contribution of platelets in the production of cryoprecipitates for use in a fibrin glue.
Rock G; Neurath D; Lu M; Alharbi A; Freedman M
Vox Sang; 2006 Oct; 91(3):252-5. PubMed ID: 16958838
[TBL] [Abstract][Full Text] [Related]
20. Fibrin(ogen)olytic character of FIIa isolated from Agkistrodon acutus venom.
Wang YW; Liang XX; Chen JS; Chen Q; Qiu PX; Lin X; Yan GM
Acta Pharmacol Sin; 2005 Jun; 26(6):691-5. PubMed ID: 15916735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
